US Pharma MarketingThe better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: BioPharma Dive